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Abstract
Background: A possible association between mucosal immunization and inflammation, as well as the initiation and
propagation of rheumatoid arthritis (RA), is attracting renewed interest. The aim of this study was to evaluate the
possible occurrence and clinical correlations of circulating secretory immunoglobulin A (SIgA) antibodies against
the second-generation cyclic citrullinated peptides (CCP) among patients with recent-onset RA followed
prospectively over 3 years.
Methods: Baseline serum samples from 636 patients with recent-onset RA were analyzed for SIgA anti-CCP
antibodies by using an enzyme-linked immunosorbent assay with a secondary antibody directed against secretory
component. SIgA anti-CCP status at baseline was analyzed in relation to smoking, HLA-DRB1/shared epitope (SE),
and the disease course over 3 years. Significant findings were evaluated in regression analysis that included age,
sex, smoking, and SE.
Results: Seventeen percent of the patients tested positive for circulating SIgA anti-CCP, and the occurrence was
confirmed by detection of secretory component in an affinity-purified IgA anti-CCP fraction. SIgA anti-CCP positivity
at baseline was associated with slightly higher baseline erythrocyte sedimentation rate (ESR) (mean 38 vs.
31 mm/first hour, p = 0.004) and C-reactive protein (CRP) (mean 30 vs. 23 mg/L, p = 0.047). During follow-up, SIgA
anti-CCP-positive patients had a higher mean AUC regarding ESR (adjusted p = 0.003), although there were no
significant differences regarding CRP, tender and swollen joint counts, or radiological joint damage (median Larsen
progression 1.0 vs. 1.0, p = 0.22). SIgA anti-CCP was associated significantly with smoking (79 % ever smokers among
SIgA anti-CCP-positive patients vs. 59 % in SIgA anti-CCP-negative patients, adjusted OR 2.19, 95 % CI 1.01–4.37,
p = 0.027) but not with carriage of the SE (80 % vs. 73 %, p = 0.62).
Conclusions: Circulating SIgA anti-CCP, which is present in a subgroup of patients with early RA, is not related to SE,
but it is environmentally linked to cigarette smoking. This finding strengthens the hypothesis that immunization
against citrullinated peptides and/or proteins may occur at mucosal surfaces of the airways. Analysis of SIgA antibodies
in serum may be a convenient and more versatile means to investigate the “mucosal connection” in RA compared
with analyses in mucosal fluid samples.
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Background
Anti-citrullinated protein antibodies (ACPA) of both the
IgG and IgA classes are commonly found in both syn-
ovial fluid and the circulation of patients with rheuma-
toid arthritis (RA) [1, 2], and they are highly specific for
the disease [3]. The occurrence of circulating immuno-
globulin A (IgA), IgM, and/or IgG ACPA often precedes
a clinical diagnosis of RA [4, 5], but it is seldom induced
after disease onset [6, 7]. Although a large number of
citrullinated autoantigens have been described, the most
commonly used ACPA test detects IgG class antibodies
to synthetic cyclic citrullinated peptides (CCP).
In recent years, the possible association between mu-
cosal immunity and the initiation and propagation of RA
has attracted renewed interest. For instance, chronic in-
flammation of the periodontium (i.e., periodontitis [PD])
associates with ACPA-positive RA, and patients with
both conditions have more severe disease than patients
with RA without PD [8, 9]. Also, IgG class serum anti-
bodies to the PD-associated bacterium Porphyromonas
gingivalis have been shown to correlate with serum
levels of IgM and IgG2 anti-CCP levels [10] as well as
with more active early disease [11]. IgG anti-CCP may
be found in fluid from gingival crevices of patients with
PD [12], and IgA anti-CCP antibodies have been demon-
strated in saliva from patients with RA [13].
Involvement of airway mucosal surfaces in ACPA induc-
tion, and subsequent RA development is frequently
brought forward, originally based on the epidemiological
connection between inhaled toxic agents (e.g., cigarette
smoke and silica) and an increased risk of ACPA-positive
RA [14–16]. Further support is provided by the findings
of ACPA enrichment in sputum and bronchoalveolar fluid
[17, 18] as signs of local autoantibody production, as well
as by the identification of identical citrullinated autoanti-
gens in both lungs and joints of patients with RA [19].
Also, radiological parenchymal abnormalities of the lungs
are more common in ACPA-positive individuals com-
pared with those who are ACPA-negative, regardless of
smoking and RA status [17, 20].
Mucosal immunity of the gastrointestinal tract re-
gained attention when it was shown in the early 1990s
that induction of oral tolerance to type II collagen could
alleviate arthritis in mice and humans, although later the
therapeutic effect in humans was found to be dis-
appointing [21]. Later work has been focused on interac-
tions with the gut microbiome, where manipulations of
the intestinal microbiota were shown to influence
arthritis severity in several animal models [22, 23].
Interestingly, patients with RA have been reported to
have an altered fecal microbiota compared with disease
controls [24], and anti-CCP antibodies and increased
total secretory IgA (SIgA) levels have been demonstrated
in feces [25].
SIgA is produced at mucosal surfaces, but it can also
be detected in low concentrations in the systemic circu-
lation [26]. In contrast to circulating IgA, which is
mostly monomeric, SIgA is mainly dimeric and com-
plexed with a secretory component (SC) (i.e., a remnant
of the polymeric immunoglobulin receptor responsible
for the active transport of antibodies across mucosal
membranes) [27]. Eijgenraam et al. reported antigen-
specific SIgA in serum after mucosal immunization with
cholera toxin subunit B [28]. Thus, mucosal immunization
in autoimmune diseases could potentially be investigated
by analysis of SIgA autoantibodies in serum, enabling
more convenient sample handling, more reliable quan-
titative analyses, and access to larger patient cohorts com-
pared with what is achievable regarding mucosal
secretions.
Before the discovery of ACPA, rheumatoid factor (RF)
was the predominant serologic marker of RA. RF of IgA
class has repeatedly been associated with smoking and
with more severe disease [29–31]. Also, RF complexed
with SC has been detected in RA, but the predictive
value of these antibodies was not evaluated [32]. The
aim of this study was to detect SIgA anti-CCP in sera
from patients with RA and to determine its relationship




Two prospective Swedish early RA cohorts, designated
“timely interventions in RA” (TIRA), formed the basis of
the present study [33]. The prerequisites for inclusion
were symptom duration ≥6 weeks but <12 months since
the first joint swelling as judged by the patient, as well
as the following:
 Fulfillment of at least four of seven of the 1987
revised American College of Rheumatology criteria
for RA [34] (n = 605 [95.1 %]) or
 Morning stiffness for ≥60 minutes and symmetrical
arthritis and small joint arthritis (fingers, wrists, or
toes) (n = 31 [4.9 %])
TIRA-1 patients were enrolled between 1996 and 1998
and prospectively followed with longitudinal assessments of
28-joint Disease Activity Score (DAS28) [35], erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), the
Swedish version of the Health Assessment Questionnaire
[36], and information regarding ongoing disease-modifying
antirheumatic drugs(DMARDs). Smoking habits were
assessed by questionnaires as previously described [37].
TIRA-2 patients were enrolled between 2006 and 2008
with identical inclusion criteria and follow-up proce-
dures as those used for TIRA-1, except that yearly
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radiographs of the hands and feet from baseline were
obtained and graded for joint damage according to the
Larsen score [38]. Smoking habits were assessed either
with a questionnaire provided by the Epidemiological
Investigations of RA Study (n = 207) [39] or by chart re-
view (n = 58).
Table 1 summarizes the baseline characteristics of
both cohorts. Baseline serum samples were available
from 197 (62.1 %) of 317 TIRA-1 patients and from 439
(97.1 %) of 452 TIRA-2 patients. There were no sig-
nificant differences in clinical characteristics between
patients who had samples available compared with those
without. All patients gave their written informed consent
to participate, and the ethics committee in Linköping,
Sweden, approved the study protocols.
Isotype-specific enzyme-linked immunoassays
Serum samples (n = 636) taken at inclusion were ana-
lyzed for anti-CCP of SIgA isotype using a modification
of the commercially available IgG class anti-CCP2
enzyme-linked immunosorbent assay (ELISA) (CCPlus®
Immunoscan; Euro Diagnostica AB, Malmö, Sweden).
Serum samples were stored at −70 °C until analysis. The
sera were diluted 1:25 with kit buffer and added in
duplicate wells. An RA reference serum with high SIgA
anti-CCP level was applied in dilution series (1:12.5 to
1:800) to achieve a standard curve and subsequent
conversion of the results into arbitrary units (AU) per
milliliter. Incubations and rinsing were done according
to the kit manufacturer’s guidelines. A polyclonal goat
IgG antihuman secretory component (GAHU/SC/PO;
Nordic BioSite, Täby, Sweden) diluted 1:2000 in kit buf-
fer was used as a secondary antibody. Absorbance was
read by spectrophotometry at 450 nm (TECAN Sunrise
software, Magellan V7.1; Tecan Nordic AB, Mölndal,
Sweden). IgG and IgA anti-CCP antibodies in TIRA-1
were analyzed by ELISAs as previously described
[6, 40] and in TIRA-2 by ELISA for IgG anti-CCP
(CCPlus® Immunoscan) and by fluorescence enzyme
immunoassays on the Phadia 250 instrument (EliA;
Thermo Fisher AB, Uppsala, Sweden) for IgA anti-CCP.
The cutoffs for a positive SIgA anti-CCP antibody test
were set to 153 AU/ml and to ≥2 μg/L for the IgA anti-
CCP EliA, both above the 99th percentile among 101
healthy blood donors. Regarding IgG anti-CCP anti-
bodies, we used the cutoff level suggested by the manu-
facturer (25 AU/ml). Citrulline specificity of the SIgA
anti-CCP method was tested by analyzing ten RA serum
samples on microtiter plates coated with cyclic arginine
peptides (CAP) (Euro Diagnostica AB) as well as on
plates coated with CCP. In total, 621 of 636 serum
samples were analyzed regarding all 3 anti-CCP isotypes
(IgG, IgA, and SIgA).
Antibody affinity purification
Anti-CCP antibodies of IgA and IgG class were isolated
from a highly positive serum sample by affinity chromatog-
raphy using aCCP column (Euro Diagnostica AB). The
sample was filtered through a 0.2-μm pore size filter and
then added to the column. Bound antibodies were eluted
using 0.1 M glycine (pH 2.7) and immediately neutralized
with 1 M Tris (pH 9.0). The CCP-specific antibodies were
then added to a protein G column (Pierce Biotechnology,
Rockford, IL, USA), and the IgG class anti-CCP antibodies
were eluted in 0.3-ml aliquots using IgG elution buffer
(Pierce Biotechnology). The flow-through (containing IgA
class anti-CCP antibodies) was added to a Peptide M col-
umn (InvivoGen, San Diego, CA, USA), and the IgA class
anti-CCP antibodies were eluted (in 0.3-ml aliquots) using
0.1 M sodium acetate (pH 4.0). Immediately after elution,
both IgG and IgA class anti-CCP antibodies were neutral-
ized with 1 M Tris-HCl (pH 8.3). The purified antibodies
were stored at −20 °C until further use.
Western blot analysis
The samples were mixed 50:50 with Laemmli buffer
containing 2-β-mercaptoethanol and heated to 95 °C for
5 minutes. The purified anti-CCP antibodies were diluted
to 0.14 μg/ml, and 35 μl of each sample was added to the
wells of a 10 % SDS-PAGE gel (Bio-Rad Laboratories,
Hercules, CA, USA), which was run for 90 minutes at
180 V (PowerPac HC; Bio-Rad Laboratories). Precision
Plus Protein WesternC Standard (Bio-Rad Laboratories)
was used as a molecular weight marker. Following elec-
trophoresis, the antibodies were transferred to a nitrocel-
lulose membrane (Bio-Rad Laboratories) presoaked in
Towbin buffer. Blotting was carried out using the Bio-Rad
PowerPac HC for 30 minutes at 80 V. The membrane
was washed and blocked using 5 % fat-free milk
Table 1 Baseline characteristics
Characteristics TIRA cohorts (n = 636)
Women 426/636 (67.0 %)
Mean age, years (SD) 57.6 (15.0)
Median baseline Larsen scorea (IQR) 2.0 (4.3)
RF-positive 387/636 (60.8 %)
IgG anti-CCP-positive 421/622 (67.7 %)
IgA anti-CCP-positive 251/635 (39.5 %)
SIgA anti-CCP-positive 110/636 (17.3 %)
Median baseline HAQ (IQR) 0.9 (0.6)
Any baseline DMARD 504/631 (79.9 %)
TIRA Swedish acronym for “timely interventions in rheumatoid arthritis”,
CCP cyclic citrullinated peptides, RF rheumatoid factor, DMARD disease-modifying
antirheumatic drug, IQR interquartile range, IgG immunoglobulin G,
IgA immunoglobulin A, SIgA secretory immunoglobulin A, HAQ Health
Assessment Questionnaire
Values are number (%) of patients unless otherwise indicated
aData available from 398 patients
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powder (Bio-Rad Laboratories) for 1 h. After blocking, the
membrane was placed in Tris-buffered saline (TBS) with
0.05 % Tween-20 (TBS-T) for 5 minutes. The molecular
weight marker was cut out and transferred to a container
with the detection antibody (Bio-Rad Laboratories) diluted
1:60,000 in TBS-T and incubated for 30 minutes, followed
by washing in TBS-T and TBS. The rest of the membrane
was transferred to a container with the SIgA detection
antibody (GAHU/SC/PO; Nordic BioSite) diluted to
1:50,000 in TBS-T and incubated overnight at 4 °C. There-
after, the membrane was washed in TBS-T and TBS,
mounted and incubated for 1 minute with the substrate
(ECL Prime Western Blotting Detection Reagent; GE
Healthcare Life Sciences, Little Chalfont, UK). The mem-
brane was exposed for 1 minute (high-performance chemi-
luminescence film; GE Healthcare Life Sciences), and the
film was developed and fixed using D-19 Silver (Kodak,
Rochester, NY, USA) and Fixer (Kodak).
Genetic analyses
In TIRA-1, genotyping of HLA-DRB1 was performed by
polymerase chain reaction amplification with sequence-
specific primers (GenoVision, Oslo, Norway); in TIRA-2,
it was carried out by Sanger sequencing (BGI Clinical
Laboratories, Shenzhen, China). In both cohorts, shared
epitope (SE) was defined as HLA-DRB1*01, *0401, *0404,
*0405, *0408, *0409, *0410, *0413, *0416, *0419, *0421,
or *10.
Statistics
Clinical and laboratory measurements of disease severity
(e.g., ESR, CRP, and DAS28) were compared by using
Student’s t test at baseline, and during follow-up by
calculating AUC for months 0–36. Missing values were
assumed to occur at random, and, unless this occurred
during the more dynamic first 6 months (which resulted
in exclusion from the analysis), we adopted the last
observation carried forward, which occurred in 4.4 % of
the occasions. Student’s t test was used to compare AUC
between patients testing positive versus negative regard-
ing anti-CCP antibodies of each isotype. Linear regres-
sion analysis was performed to evaluate the association
between SIgA anti-CCP and ESR adjusted for age, sex,
and carriage of SE. As IgG anti-CCP is well known to
associate with the disease course in early RA, and since
SIgA/IgA anti-CCP antibodies almost exclusively occur
in IgG anti-CCP-positive patients, we chose to evaluate
the influence of SIgA and IgA anti-CCP antibodies on
disease course and pharmacotherapy in IgG anti-CCP-
positive patients only.
The Mann-Whitney U test was applied to evaluate dif-
ferences between anti-CCP levels and radiological joint
Fig. 1 Occurrence of immunoglobulin A (IgA) and secretory IgA (SIgA) anti-cyclic citrullinated protein (anti-CCP) antibodies in patients with early
rheumatoid arthritis (RA) testing positive (a) or negative (b) for IgG anti-CCP. SIgA reactivity to CCP and cyclic arginine peptide (CAP) in ten pa-
tients with RA (c), and SIgA anti-CCP levels in patients with RA and control subjects (d). AU arbitrary units
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damage. Spearman´s correlation (ρ) was used to evaluate
correlations between levels of SIgA anti-CCP, other
ACPA isotypes, and baseline disease activity measures.
Fisher’s exact test was performed to test differences in
the occurrence of SE and smoking. Also, the association
between smoking and SIgA anti-CCP was tested in a
logistic regression analysis, adjusting for age, sex, and
carriage of SE. Statistical analyses were performed using
IBM SPSS 22.0 software (IBM, Armonk, NY, USA), and
two-sided p values less than 0.05 were considered
significant.
Results
Occurrence of SIgA anti-CCP
As measured by ELISA, circulating SIgA anti-CCP oc-
curred in 29 (14.7 %) TIRA-1 patients and 81 (18.5 %)
TIRA-2 patients, respectively (17.3 % occurrence in
total) (Fig. 1a–d). Among patients with IgG anti-CCP
antibodies, 25.4 % also had SIgA anti-CCP antibodies,
while IgA anti-CCP antibodies occurred in 38.6 %
(Fig. 1a, b). SIgA anti-CCP and IgA anti-CCP were both
rare in the absence of IgG anti-CCP antibodies (occurring
in 2 and 10 patients, respectively). Ninety-six (15.5 %) of
six hundred twenty-one of the patients tested positive for
all analyzed isotypes.
Citrulline-dependent specificity of the SIgA antibodies
was evaluated by testing the reactivity to CAP control
plates in ten anti-CCP-positive serum samples. The me-
dian optical density (OD) for SIgA anti-CAP was 0.09
(range 0.05–0.27), and the median OD for SIgA anti-CCP
was 0.83 (range 0.18–2.63) for the same serum samples
(Fig. 1c). No SIgA anti-CAP value exceeded 40 % of the
corresponding SIgA anti-CCP OD. SIgA anti-CCP levels
correlated significantly with IgG anti-CCP (ρ = 0.70,
p < 0.001) and with levels of IgA anti-CCP (ρ = 0.69 in
TIRA-1 and ρ = 0.64 in TIRA-2, p < 0.001 for both;
cohorts presented separately because of different detection
methods used).
To confirm the presence of circulating SIgA anti-CCP,
we performed Western blot analysis to detect SC in
affinity-purified anti-CCP antibodies from IgG and IgA
fractions of patient sera. In the IgA anti-CCP eluate, an
80 kDa band appeared, corresponding to the molecular
weight of SC [27], while no band was visible in the IgG
anti-CCP fraction (Fig. 2).
Circulating SIgA anti-CCP and disease outcome
A modest but statistically significant correlation was
observed between levels of SIgA anti-CCP and ESR at
baseline (ρ = 0.09, p = 0.02), while the number of
tender and swollen joints at baseline tended to be
inversely correlated with SIgA anti-CCP levels (ρ = −0.12,
p = 0.002, and ρ = −0.08, p = 0.038, respectively). There
were no significant correlations regarding baseline DAS28
(ρ = −0.06, p = 0.15) or CRP (ρ = −0.02, p = 0.65).
As IgG anti-CCP antibody status is known to predict
the disease course [6] and therefore may influence thera-
peutic decisions in early RA, and since SIgA anti-CCP
almost exclusively occurs in IgG anti-CCP-positive pa-
tients, we chose to perform analyses of disease severity
only among the IgG anti-CCP-positive patients. Patients
testing positive regarding SIgA (and IgG) anti-CCP had
higher mean baseline CRP and ESR levels than the pa-
tients negative for SIgA (but still positive regarding IgG)
anti-CCP (CRP 29.9 vs. 22.7 mg/L, p = 0.047; ESR 38.0
vs. 30.8 mm/first hour, p = 0.004). There were no signifi-
cant differences between the two groups regarding base-
line DAS28 (5.1 vs. 5.1, p = 0.57), tender joint count (7.1
vs. 7.9, p = 0.24), or swollen joint count (8.1 vs. 7.9,
p = 0.73). Patients testing positive for SIgA anti-CCP
had higher baseline levels of both IgG and IgA anti-CCP
than SIgA-negative patients (median IgG in TIRA-1 1270
vs. 424 AU/ml, p < 0.001; median IgA in TIRA-1 77.5 vs.
58.5 AU/ml, p < 0.001; median IgA in TIRA-2 10.5 vs.
5.5 μg/L, p < 0.001).
Fig. 2 Western blotting for the detection of secretory component in an
(A) immunoglobulin G (IgG) anti-cyclic citrullinated protein (anti-CCP)
antibody fraction and (B) an IgA anti-CCP fraction. An 80 kDa
band corresponding to the secretory component is visible in the
IgA anti-CCP fraction
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As seen in Fig. 3, comparison of AUC for the 3-year
follow-up period revealed significantly higher mean ESR
among SIgA-positive patients (p = 0.005) but no signifi-
cant differences regarding CRP, DAS28, and swollen or
tender joint count. In univariate analyses of IgG anti-
CCP-positive patients, SIgA anti-CCP status and age
(but not sex, smoking, or SE) were significantly associ-
ated with AUC ESR. In a linear regression analysis
adjusting for age, SIgA anti-CCP positivity remained
significantly associated with higher mean AUC for ESR
(p = 0.003). In a similar model, but analyzing absolute
values at the 3-year follow-up, SIgA anti-CCP positivity
was associated with a 5.0 mm/first hour increase in ESR
(95 % CI 0.7–9.2) compared with SIgA anti-CCP-
negative patients.
IgA anti-CCP status was evaluated using the same ap-
proach, and no significant differences were detected in
AUC of the above-mentioned disease activity measures
(data not shown). The proportion of patients prescribed
DMARD or nonsteroidal anti-inflammatory drug (NSAID)
treatment did not differ between SIgA-positive and SIgA-
negative patients at any of the follow-up visits (data not
shown). Radiological joint damage in the TIRA-2 cohort
did not significantly differ between SIgA anti-CCP-positive
and SIgA anti-CCP-negative patients at baseline (median
Larsen score 2.0 vs. 2.0, p = 0.61) or at the 3-year follow-
Fig. 3 Three-year disease course of early rheumatoid arthritis in relation to secretory immunoglobulin A (SIgA) anti-cyclic citrullinated peptide
(anti-CCP) antibody status as mirrored by (a) erythrocyte sedimentation rate (ESR), (b) C-reactive protein (CRP), (c) 28-joint Disease Activity Score
(DAS28), (d) swollen joint count, and (e) tender joint count. Mean values are shown, and p values refer to differences in AUC
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up visit (2.5 vs. 4.0, p = 0.42). Likewise, there was no
difference in median Larsen score progression over 3 years
(1.0 vs. 1.0, p = 0.22).
Circulating SIgA anti-CCP in relation to HLA-DRB1/shared
epitope and smoking habit
At least one SE allele was present in 83 (80 %) of the
SIgA anti-CCP patients and in 340 (73 %) of the SIgA
anti-CCP-negative patients. As seen in Fig. 4a, carriage
of SE was associated with IgG anti-CCP antibodies
(p = 0.0001) but not with the co-occurrence of SIgA anti-
CCP (p = 0.44). Smoking habits were analyzed in the same
way as SE (Fig. 4b), where 53 (79 %) of the SIgA anti-
CCP-positive patients were ever smokers, compared with
168 (59 %) of the SIgA-negative patients. Ever smoking
was associated with the presence of SIgA anti-CCP anti-
bodies (p = 0.0095), while IgG anti-CCP antibodies (in the
absence of SIgA anti-CCP) was not (p = 0.26). Smoking
was significantly associated with the presence of SIgA
anti-CCP (OR 2.19, 95 % CI 1.01–4.37, p = 0.027), also
after adjusting for age, sex, and SE (Table 2).
Discussion
In this study of well-characterized patients with early
RA, we present the novel finding of circulating SIgA
anti-CCP and describe its relationship to disease severity
and etiological factors. Unlike IgG anti-CCP, circulating
SIgA anti-CCP is not genetically related to SE, but is en-
vironmentally linked to cigarette smoking. This corre-
sponds well to our previous studies regarding serum IgA
ACPA, in which detection antibodies to α-chains were
used and thus, as monomeric IgA predominates in the
circulation, mainly concern nonsecretory IgA [16, 40].
Although secretory autoantibodies in sera from patients
with other autoimmune diseases have been described
earlier [32, 41], to the best of our knowledge this is the
first report on SIgA ACPA in RA.
We found that approximately 25 % of patients with
early RA with IgG class anti-CCP antibodies also had
circulating SIgA anti-CCP antibodies, a proportion that
is lower than IgA anti-CCP antibodies (39 %), which
supports the notion that nonsecretory forms of IgA anti-
CCP prevail in the circulation. The correlation between
levels of SIgA anti-CCP and levels of IgG anti-CCP was
found to be equally as strong as between SIgA and IgA
anti-CCP. This somewhat surprising finding may suggest
that mucosal immunization to citrullinated proteins is
similarly important in systemic IgG and IgA ACPA
responses in early RA. However, to enable firm conclu-
sions regarding the temporal relationship between SIgA
and other isotypes, serial analyses of preclinical cases are
warranted. Also, it remains to be determined if and
where mucosal immunization against citrullinated pro-
teins occurs in IgG+/IgA−/SIgA− patients.
Fig. 4 Secretory immunoglobulin A (SIgA) and immunoglobulin G
(IgG) anticyclic citrullinated protein antibodies in relation to (a) shared
epitope (SE) and (b) smoking in patients with early rheumatoid arthritis
Table 2 Logistic regression analysis regarding secretory anti-cyclic citrullinated protein antibodies in patients with early
rheumatoid arthritis
Variable SIgA anti-CCP Unadjusted Adjusted
Positive Negative p value OR (95 % CI) p value OR (95 % CI)
Ever smoking 49/63 (78 %) 94/156 (60 %) 0.015 2.31 (1.18–4.53) 0.027 2.19 (1.01–4.37)
One or two SE alleles 51/63 (81 %) 130/156 (83 %) 0.674 0.85 (0.40–1.81) 0.819 0.91 (0.42–2.00)
Female sex 44/63 (70 %) 117/156 (75 %) 0.434 1.30 (0.68–2.48) 0.814 1.09 (0.55–2.14)
Age at inclusion, years 58.7 52.6 0.002 1.04 (1.02–1.07) 0.005 1.04 (1.01–1.07)
SE Shared epitope, SIgA secretory immunoglobulin A, CCP cyclic citrullinated protein
Adjusted values are adjusted for all other variables in the table
Roos et al. Arthritis Research & Therapy  (2016) 18:119 Page 7 of 9
On the basis of our previous findings of a milder
disease in patients with RA with salivary IgA anti-CCP
[13], we anticipated that circulating SIgA anti-CCP
would associate with lower disease activity at the time of
sampling, and possibly over time in early disease. In-
stead, it turned out that SIgA anti-CCP-positive patients
had higher ESR and CRP levels at baseline than SIgA
anti-CCP-negative patients, and the difference remained
significant over 3 years regarding ESR. Although these
findings are in line with previous reports on IgA RF, we
did not find any significant predictive value of IgA anti-
CCP in our cohorts. Intriguingly, while baseline inflam-
matory activity was higher in patients with SIgA anti-
CCP antibodies, the number of swollen and tender joints
was inversely related to SIgA anti-CCP antibody levels at
the time of sampling. This finding opens up for specula-
tion that the laboratory markers of inflammation partly
reflect mucosal inflammation and not merely synovitis.
Instead, the inverse correlation between antibody levels
and effects on joints could hypothetically reflect the
downregulating potential of antigen exposure in the
gastrointestinal tract (i.e., oral tolerance). However, this
remains speculative, as the origin of circulating SIgA
anti-CCP remains to be determined. Further, it is pos-
sible that SIgA anti-CCP correlates with total IgA levels,
which in turn may influence the ESR without being re-
lated to inflammation. In view of the small differences in
disease activity measures over time as well as the lack of
association with radiological progression, we see no clin-
ical reason at present for routine baseline testing of SIgA
anti-CCP. We recently reported that IgA and SIgA anti-
proteinase 3 (PR3) antibodies are more closely related to
disease activity than IgG anti-PR3 in antineutrophil cyto-
plasmic antibody-associated vasculitis [42]. Analogously,
future work should evaluate changes in SIgA anti-CCP
levels in relation to therapeutic responses. Also, serial
SIgA anti-CCP analyses in serum from pre-RA patients
are of obvious interest regarding mucosal involvement in
disease development.
Passive transport over leaky, inflamed mucosal mem-
branes could be one possibility by which SIgA is translo-
cated from mucosal secretions to the systemic circulation.
However, there are several examples of active retrans-
portation of SIgA across mucosal membranes from the
luminal side to the subepithelial compartment [43, 44] and
even inducing systemic immunity [45], but how SIgA is
further transferred into the circulation remains unknown.
Total SIgA levels in the circulation are elevated in pa-
tients with RA compared not only with healthy individ-
uals but also with patients with ankylosing spondylitis
(i.e., another rheumatic disease with mucosal pathogenic
implications) [32, 46]. In line with previous work regard-
ing SIgA [46], we found no relationship between SIgA
anti-CCP levels and use of NSAIDs, suggesting that
iatrogenic damage to mucosal membranes is not a major
cause of SIgA occurrence in the circulation. Cigarette
smoking, on the other hand, appears robustly associated
with serum SIgA anti-CCP antibody occurrence, even
after considering the presence of IgG anti-CCP. Al-
though not explicitly addressed in the present study, this
finding may suggest that the airway mucosa is a major
contributor to serum SIgA anti-CCP. Paired samples of
serum and mucosal fluid from patients with RA will be
crucial to delineating the origin of serum SIgA ACPAs
and to determining the pathogenic role of each mucosal
compartment.
Conclusions
SIgA anti-CCP antibodies can be detected in serum from
patients with RA and are associated with smoking and
increased signs of systemic inflammation at the time of
sampling.
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